

April 28, 2026 02:02 AM GMT

Greater China Semiconductors | Asia Pacific

Old Memory – Reaffirming Asymmetric Risks

We see ongoing upside on legacy Flash and 2.5D IPD/3D WoW memory. Reiterate OW on Macronix and AP Memory; raise AP Memory PT further.

Key Takeaways

- Intel continues to make progress on advanced packaging, suggesting upside on AP Memory IPD in 2028.
- Higher DRAM pricing could suggest WoW pricing renegotiation, enlarging TAM.
- Macronix earnings suggests continued pricing upside in 2H for MLC NAND and NOR.

Higher DRAM pricing and Intel's commentary suggests upside SiCap and WoW

TAM: Intel mentioned that the company continued to make progress on advanced packaging, including additional growth in customer backlog ([link](#)). We believe EMIB-T will be the important packaging technology with Mediatek's TPU ([link](#)). If there are additional clients, there could be potential upside on SiCap TAM ([link](#)). We also believe WoW TAM could be larger given the much higher DRAM cost ([link](#)). Our prior assumption of ASP US\$6 per GB appears to be too low vs. DRAM pricing above US\$15.

Macronix earnings suggested upside on MLC (Exhibit 2): strong 1Q results beat was helped by eMMC (MLC) which recorded +94% Q/Q growth and +3,994% Y/Y growth. Management sees large undersupply for eMMC, and expects continued pricing upside in 2H for eMMC and NOR. The company also expects GM improvement to continue.

DDR4 remains strong but upside likely capped: According to the Taiwan local news, Nanya Tech will penetrate into the VR supply chain through LPDDR offering; that said, we think the news could be misleading as we believe the SOCAMM2 will require LPDDR5X, which we haven't seen the sample from the company. In the near term, we continue to see pricing hike into 3Q but likely capped on US\$25 per GB even for networking clients. Meanwhile, we do see GigaDevice trying to ramp up 16G LPDDR4 and 32G DDR4 based on gen 4 technology.

Keeping our selective view; up AP Memory PT: We revise up AP Memory's PT to NT\$1,000; we estimate its earnings to grow 60%+ in both 2027 and 2028, boosted by SiCap and WoW. We estimate 74% of the revenue coming from these new opportunities in 2028. For Macronix, we retain OW and our Top Pick.

MORGAN STANLEY TAIWAN LIMITED+

Daniel Yen, CFA

Equity Analyst

Daniel.Yen@morganstanley.com

+886 2 2730-2863

Charlie Chan

Equity Analyst

Charlie.Chan@morganstanley.com

+886 2 2730-1725

MORGAN STANLEY ASIA LIMITED+

Daisy Dai, CFA

Equity Analyst

Daisy.Dai@morganstanley.com

+852 2848-7310

MORGAN STANLEY TAIWAN LIMITED+

Tiffany Yeh

Equity Analyst

Tiffany.Yeh@morganstanley.com

+886 2 7712-3032

MORGAN STANLEY ASIA LIMITED+

Ethan Jia

Research Associate

Ethan.Jia@morganstanley.com

+852 3963-2287

GREATER CHINA TECHNOLOGY SEMICONDUCTORS

Asia Pacific

Industry View

Attractive

WHAT'S CHANGED

AP Memory Technology Corp (6531.TW)	From	To
Price Target	NT\$777.00	NT\$1,000.00

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+ = Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Reaction to earnings

Impact to our thesis	Financial results versus consensus	Direction of next 12-month consensus EPS
----------------------	------------------------------------	--

Macronix International Co Ltd (2337.TW)

Strengthens our thesis	↑ Modest upside	↑ Modest revision higher
------------------------	-----------------	--------------------------

Source: Company data, Morgan Stanley Research

Key Charts and Exhibits

Exhibit 1: Order of preference: GC memory

	Macronix 2337.TW	AP Memory 6531.TW	PSMC 6770.TW	GigaDevice 603986.SS	Nanya Tech 2408.TW	Winbond 2344.TW
Rating	Overweight	Overweight	Overweight	Overweight	Equal-Weight	Equal-Weight
Trading Currency	TWD	TWD	TWD	CNY	TWD	TWD
Price Target	202.0	1,000.0	71.0	348.0	278.0	100.0
Current Price (as of 2026/4/27)	145.0	753.0	54.5	303.4	226.5	93.9
Upside/(Downside) (%)	39%	33%	30%	15%	23%	6%
Market Cap (in USD mm)	8,321.4	3,874.8	7,173.8	29,626.4	22,198.4	12,481.0
Avg Daily Traded Vol (in USD mm)	149.6	53.2	166.5	906.9	456.5	295.0
Street View: Ratings						
Buy/Overweight	90%	100%	50%	92%	75%	80%
Hold/Equal-weight	0%	0%	50%	5%	19%	20%
Sell/Underweight	10%	0%	0%	0%	6%	0%
Bull Case Value	326.0	1,175.0	113.6	604.0	588.0	120.0
Upside (%)	125%	56%	108%	99%	160%	28%
Bear Case Value	119.5	400.0	35.5	219.0	155.0	41.4
Downside (%)	-18%	-47%	-35%	-28%	-32%	-56%
Risk/Reward Skew	7.1	1.2	3.1	3.6	5.1	0.5
Morgan Stanley Estimates						
FY26e	TWD	TWD	TWD	CNY	TWD	TWD
Sales	66,682	9,333	66,303	17,061	301,785	224,249
EBITDA	24,507	2,901	12,145	6,005	217,986	106,288
EBIT	16,970	2,841	4,581	5,736	205,800	90,677
EPS	7.35	16.16	8.61	8.10	53.71	16.57
FY27e						
Sales	126,013	14,326	72,058	24,555	377,418	264,897
EBITDA	54,966	5,077	18,971	9,504	265,451	129,416
EBIT	48,496	5,014	11,931	9,235	242,266	109,239
EPS	20.82	27.19	2.21	12.98	62.86	19.87
FY26 MSe vs. Consensus Mean						
Sales	-5.4%	7.0%	-1.8%	18.0%	24.7%	8.3%
EBITDA	-0.7%	-1.2%	-58.6%	2.3%	32.9%	5.8%
EBIT	-30.9%	12.9%	-76.9%	11.1%	27.3%	6.8%
EPS	-35.5%	-10.7%	49.8%	11.2%	29.8%	7.7%
FY27 MSe vs. Consensus Mean						
Sales	12.9%	3.3%	-9.5%	35.4%	32.9%	-1.0%
EBITDA	2.8%	3.3%	-34.8%	31.7%	39.2%	-1.8%
EBIT	20.5%	4.6%	-30.5%	36.2%	30.3%	3.2%
EPS	-26.9%	1.5%	-34.9%	36.9%	34.7%	-3.4%
Valuation Multiples at Last Close						
FY26e						
P/E	19.7x	46.6x	6.3x	37.5x	4.2x	5.7x
EV/EBIT	24.2x	52.9x	23.7x	38.2x	5.0x	4.9x
EV/EBITDA	12.5x	38.0x	7.5x	31.5x	4.0x	3.9x
EV/Sales	4.6x	11.8x	1.4x	11.1x	2.9x	1.8x
FCF Yield	-12.5%	1.5%	53.0%	2.2%	-30.4%	9.5%
FY27e						
P/E	7.0x	27.7x	24.7x	23.4x	3.6x	4.7x
EV/EBIT	5.5x	21.6x	7.4x	19.8x	2.7x	2.8x
EV/EBITDA	4.9x	21.4x	4.7x	19.3x	2.4x	2.4x
EV/Sales	2.1x	7.6x	1.2x	7.5x	1.7x	1.1x
FCF Yield	16.4%	2.8%	5.8%	3.8%	32.0%	30.4%
Implied Multiples on MS Price Target						
FY26e						
P/E	27.5x	61.9x	8.2x	43.0x	5.2x	6.0x
EV/EBIT	24.2x	52.9x	23.7x	38.2x	5.0x	4.9x
EV/EBITDA	16.7x	51.7x	8.9x	36.4x	4.7x	4.1x
EV/Sales	6.1x	16.1x	1.6x	12.8x	3.4x	2.0x
FY27e						
P/E	9.7x	36.8x	32.2x	26.8x	4.4x	5.0x
EV/EBIT	7.7x	33.1x	25.2x	28.5x	3.6x	3.9x
EV/EBITDA	6.8x	32.7x	15.9x	27.7x	3.3x	3.3x
EV/Sales	3.0x	11.6x	4.2x	10.7x	2.3x	1.6x


Source: FactSet, Morgan Stanley Research (e) estimates. Pricing as of April 27, 2026.

Exhibit 2: Macronix 1Q26 earnings results

P/L Comparison (NT\$ mn)	1Q26						
	1Q25	4Q25	1Q26	Q/Q	Y/Y	MSe.	Diff.
Net sales	6,137	7,729	10,469	35%	71%	8,973	17%
Gross profit	1,087	1,868	4,271	129%	293%	3,020	41%
Operating profit	-1,082	-392	1,933			660	193%
Pretax profit	-969	-302	2,066			583	255%
Net profit	-873	-295	1,776			492	261%
EPS (NT\$)	-0.47	-0.16	0.90			0.26	242%
Key ratios (%)							
Gross margin	17.7%	24.2%	40.8%	16.6 ppt	23.1 ppt	24.7%	16.1 ppt
Operating margin	-17.6%	-5.1%	18.5%	23.5 ppt	36.1 ppt	-2.1%	20.5 ppt
Pretax margin	-15.8%	-3.9%	19.7%	23.7 ppt	35.5 ppt	-2.8%	22.6 ppt
Net profit margin	-14.2%	-3.8%	17.0%	20.8 ppt	31.2 ppt	-2.4%	19.4 ppt


Source: Company data, Morgan Stanley Research

Exhibit 3: NOR flash demand and supply growth rates




Source: Company data, Morgan Stanley Research

Exhibit 4: NOR flash demand growth and supply growth by density




Source: Company data, Morgan Stanley Research

Exhibit 5: DDR4 quarterly supply and demand summary




Source: Morgan Stanley Research (e) estimates

Exhibit 6: Quarterly oversupply/undersupply ratio vs. Nanya and Winbond pricing Q/Q change




Source: Morgan Stanley Research (e) estimates

Exhibit 7: Quarterly supply breakdown (mn Gb)




Source: Morgan Stanley Research (e) estimates

Exhibit 8: Quarterly demand breakdown by product (mn Gb)




Source: Morgan Stanley Research (e) estimates

Exhibit 9: Memory vendors GM




Source: Company data, Morgan Stanley Research estimates

Exhibit 10: Memory vendors OPM




Source: Company data, Morgan Stanley Research

Exhibit 11: DDR4 8Gb (1Gx8) pricing chart



Source: DRAMeXchange, Morgan Stanley Research; data as of Mar 13, 2026

Exhibit 12: DDR5 16Gb (2Gx8) pricing chart




Source: DRAMeXchange, Morgan Stanley Research; data as of Mar 13, 2026

AP Memory: Bottom-up Analysis for IPD Business; Intel EMIB Opportunity

According to Intel (covered by Joseph Moore), to further stabilize power delivery, Intel Foundry integrates embedded deep trench capacitors (eDTC) for ultra-high capacitance density close to the load, thereby flattening PDN impedance across the base die. Embedded MIM (eMIM-T) technology delivers superior decoupling at the base die, leveraging the same advanced architecture as Omni MIM even on mature nodes. For precise, high-speed point-of-load regulation, CoaxMIL technology embeds magnetic inductors into the substrate, enabling integrated voltage regulators (IVRs) with rapid response and minimal loss. Together, these technologies form a scalable power delivery fabric that keeps pace with rising compute density. We believe these eDTC are IPD products that AP Memory provides.

Exhibit 13: An example of Intel Foundry's power delivery solution shown at Intel Direct Connect 2025, showcasing forward-looking plans for increased eMIM-T capacity; we think this is adopting AP Memory's IPD, which is the eDTC here



Source: Intel

Exhibit 14 outlines our estimation for projected contributions to AP memory revenues from 2026 to 2028 across IPD's customer. Humufish is expected to ship ~2 million TPUs at 100 IPD per chip, generating about \$160 million (NT\$4.8 billion) in revenue, as we need to consider the yield rate. China AI GPU demand grows significantly, with total shipments rising from 1,992k units in 2026 to 4,966k in 2028, led by vendors such as Huawei, Cambricon, and T-Head, driving revenue from \$40 million to \$168 million (NT\$1.2 billion to NT\$5.0 billion). Broadcom's Tomahawk 6 CoWoS bookings contribute around \$69 million (NT\$2.07 billion) in 2026e. Altogether, total IPD revenue contribution to AP memory is projected to increase from NT\$3.27 billion in 2026 to NT\$10.04 billion by 2028, reflecting strong growth driven primarily by China's AI GPU expansion and steady contributions from networking and specialized applications.

Exhibit 14: Bottom-up Analysis for IPD Business

	2026	2027	2028
Humufish			
TPU v10 2nm Humufish shipment (k units)			2,000
IPD per chip			100
Humufish IPD number (mn units)			200
IPD ASP (US\$)			0.8
Revenue contribution from Humufish (US\$m)			160
Revenue contribution from Humufish (NT\$m)			4,800
China AI GPU			
Total China GPU shipment (k units)	1,992	3,550	4,966
Huawei	900	1,500	2,100
Cambricon	280	440	600
Hygon (GPU only)	130	170	270
MetaX	75	115	140
T-Head (GPU only)	250	450	550
Kunlun	130	270	340
MooreThread	40	85	120
Biren	27	85	125
Iluvatar CoreX	100	250	380
Enflame	40	55	71
Bytedance ASIC	20	130	270
IPD per China GPU chip	40	45	45
IPD ASP (US\$)	0.5	0.8	0.8
Revenue contribution from China GPU (US\$m)	40	120	168
Revenue contribution from China GPU (NT\$m)	1,195	3,594	5,028
Broadcom			
Tomhawk 6 CoWoS booking (k units)	23		
IPD Required per CoWoS Wafers	1		
IPD Interposer ASP (US\$k)	3		
Revenue contribution from Tomhawk (US\$m)	69		
Revenue contribution from Tomhawk (NT\$m)	2,070		
Others			
Others (e.g. NRE; NT\$m)	62	2,170	226
Total IPD Revenue Contribution to AP Memory	3,265	3,594	9,828

Source: Company data, Morgan Stanley Research estimates

Macronix: Earnings Estimate Revisions

We raise our 2026/27/28 EPS forecasts by 25%/6%/9%: We factor in 1Q26 results. We continue to believe MLC and legacy TLC NAND will face a deeper shortages into 2H, with undersupply likely rising to ~40%. Global capacity for 2GB to 64GB NAND has largely disappeared, and customer inventory generally lasts only another 6–9 months. Macronix remains the only supplier able to fill the gap. We expect MLC and legacy TLC pricing to rise more than 200% from 1Q26 to 4Q26.

We expect NOR Flash pricing to rise 20–30% in 1Q, with further upside in 2Q, and visibility for continued hikes now extending into 2H26. We also expect global mainstream vendors to reduce NOR capacity. Demand for legacy ROM should strengthen as the Nintendo Switch 2 ramps.

After revisions, our 2026/27/28 EPS forecasts are NT\$7.35/20.82/21.42 vs. FactSet consensus of NT\$12.94/27.43/41.02, as we continue to monitor the pricing trends of MLC NAND.

Exhibit 15: Macronix: Earnings Estimate Revisions

(NT\$ mn)	New 2026e	Old 2026e	Diff.%	New 2027e	Old 2027e	Diff.%	New 2028e	Old 2028e	Diff.%
Net sales	66,682	56,677	18%	126,013	109,328	15%	127,564	109,792	16%
Gross profit	27,925	23,991	16%	61,874	55,079	12%	63,549	55,620	14%
Operating profit	16,970	13,412	27%	48,496	43,644	11%	49,869	43,561	14%
Pretax income	17,076	12,986	31%	48,421	43,168	12%	49,813	43,111	16%
Net income	14,478	10,994	32%	40,998	36,558	12%	42,178	36,511	16%
Diluted EPS	7.35	5.90	25%	20.82	19.61	6%	21.42	19.58	9%
Margins									
Gross margin	41.9%	42.3%	-0.5 ppt	49.1%	50.4%	-1.3 ppt	49.8%	50.7%	-0.8 ppt
Operating margin	25.4%	23.7%	1.8 ppt	38.5%	39.9%	-1.4 ppt	39.1%	39.7%	-0.6 ppt
Pretax margin	25.6%	22.9%	2.7 ppt	38.4%	39.5%	-1.1 ppt	39.0%	39.3%	-0.2 ppt
Net margin	21.7%	19.4%	2.3 ppt	32.5%	33.4%	-0.9 ppt	33.1%	33.3%	-0.2 ppt

Source: Company data, Morgan Stanley Research (E) estimates

Exhibit 16: Macronix: BVPS Estimate Revisions

NT\$	New '26E	Old '26E	Diff.	New '27E	Old '27E	Diff.	New '28E	Old '28E	Diff.
BVPS	28.92	28.67	1%	49.74	48.28	3%	71.17	67.86	5%

Source: Company data, Morgan Stanley Research (E) estimates

Exhibit 17: Macronix: Quarterly financials


(NT\$ mn)	1Q26e	2Q26e	3Q26e	4Q26e	1Q27e	2Q27e	3Q27e	4Q27e	1Q28e	2Q28e	3Q28e	4Q28e	2025	2026e	2027e	2028e
Total Revenues	10,469	12,969	17,087	26,157	29,574	32,494	31,989	31,957	31,928	31,902	31,878	31,857	28,880	66,682	126,013	127,564
Sequential Change	35.4%	23.9%	31.8%	53.1%	13.1%	9.9%	-1.6%	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%				
Change vs Year Ago	70.6%	90.7%	108.0%	238.4%	182.5%	150.6%	87.2%	22.2%	8.0%	-1.8%	-0.3%	-0.3%	11.6%	130.9%	89.0%	1.2%
Cost of Sales	(6,198)	(7,771)	(10,303)	(14,486)	(15,269)	(16,328)	(15,787)	(15,762)	(15,737)	(15,737)	(15,737)	(15,716)	(23,749)	(38,757)	(64,140)	(64,015)
Gross Profit	4,271	5,198	6,784	11,671	14,304	16,166	16,202	16,196	16,191	16,165	16,141	16,140	5,131	27,925	61,874	63,549
Gross Margin	40.8%	40.1%	39.7%	44.6%	48.4%	49.8%	50.6%	50.7%	50.7%	50.7%	50.6%	50.7%	17.8%	41.9%	49.1%	49.8%
Total Opex	(2,339)	(2,569)	(2,791)	(3,256)	(3,468)	(3,631)	(3,627)	(3,645)	(3,664)	(3,682)	(3,701)	(3,720)	(8,829)	(10,955)	(14,372)	(14,768)
Percent of Revenues	22.3%	19.8%	16.3%	12.4%	11.7%	11.2%	11.3%	11.4%	11.5%	11.5%	11.6%	11.7%	30.6%	16.4%	11.4%	11.6%
R&D	(1,411)	(1,431)	(1,451)	(1,471)	(1,491)	(1,511)	(1,531)	(1,551)	(1,571)	(1,591)	(1,611)	(1,631)	(5,714)	(5,764)	(6,084)	(6,404)
Percent of Revenues	13.5%	11.0%	8.5%	5.6%	5.0%	4.6%	4.8%	4.9%	4.9%	5.0%	5.1%	5.1%	19.8%	8.6%	4.8%	5.0%
Sales and Marketing	(425)	(636)	(837)	(1,282)	(1,449)	(1,593)	(1,568)	(1,566)	(1,565)	(1,564)	(1,562)	(1,561)	(1,520)	(3,180)	(6,176)	(6,252)
Percent of Revenues	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	5.3%	4.8%	4.9%	4.9%
General and Admin	(503)	(503)	(503)	(503)	(528)	(528)	(528)	(528)	(528)	(528)	(528)	(528)	(1,594)	(2,011)	(2,112)	(2,112)
Percent of Revenues	4.8%	3.9%	2.9%	1.9%	1.8%	1.6%	1.7%	1.7%	1.7%	1.7%	1.7%	1.7%	5.5%	3.0%	1.7%	1.7%
Operating Income	1,933	2,628	3,993	8,416	10,836	12,534	12,575	12,551	12,527	12,483	12,440	12,420	(3,698)	16,970	48,496	49,869
Percent of Revenues	18.5%	20.3%	23.4%	32.2%	36.6%	38.6%	39.3%	39.3%	39.2%	39.1%	39.0%	39.0%	-12.8%	25.4%	38.5%	39.1%
Total Non-operating Income(Loss)	134	10	(19)	(19)	(19)	(18)	(19)	(20)	(20)	(13)	(12)	(11)	64	106	(75)	(56)
Profit Before Taxes	2,066	2,638	3,974	8,397	10,817	12,516	12,556	12,531	12,507	12,470	12,428	12,409	(3,633)	17,076	48,421	49,813
Percent of Revenues	19.7%	20.3%	23.3%	32.1%	36.6%	38.5%	39.3%	39.2%	39.2%	39.1%	39.0%	39.0%	-12.6%	25.6%	38.4%	39.0%
Change vs Year Ago	-313.2%	-287.4%	-516.7%	-2876.3%	423.5%	374.4%	215.9%	49.2%	15.6%	-0.4%	-1.0%	-1.0%				
Taxes	(287)	(404)	(608)	(1,285)	(1,655)	(1,915)	(1,921)	(1,917)	(1,914)	(1,908)	(1,901)	(1,899)	328	(2,583)	(7,408)	(7,621)
Tax Rate	15.3%	15.3%	15.3%	15.3%	15.3%	15.3%	15.3%	15.3%	15.3%	15.3%	15.3%	15.3%	9.0%	15.1%	15.3%	15.3%
Net Income, Cont Ops	1,779	2,235	3,366	7,112	9,162	10,601	10,635	10,614	10,593	10,562	10,526	10,510	(3,305)	14,492	41,013	42,192
Percent of Revenues	17.0%	17.2%	19.7%	27.2%	31.0%	32.6%	33.2%	33.2%	33.2%	33.1%	33.0%	33.0%	-11.4%	21.7%	32.5%	33.1%
Minority Interest	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(3)	(14)	(14)	(14)
Reported Income (TW GAAP)	1,776	2,231	3,363	7,109	9,159	10,598	10,632	10,610	10,590	10,559	10,523	10,507	(3,308)	14,478	40,998	42,178
Percent of Revenues	17.0%	17.2%	19.7%	27.2%	31.0%	32.6%	33.2%	33.2%	33.1%	33.0%	33.0%	33.0%	-11.5%	21.7%	32.5%	33.1%
Change vs Year Ago	-303.4%	-274.8%	-489.5%	-2507.8%	415.7%	375.0%	216.2%	49.3%	15.6%	-0.4%	-1.0%	-1.0%	2.9%	-537.7%	183.2%	2.9%
Reported Diluted EPS (NT\$, TW GAAP)	0.90	1.13	1.71	3.61	4.65	5.38	5.40	5.39	5.38	5.36	5.34	5.34	(1.78)	7.35	20.82	21.42
Reported Basic EPS (NT\$, GAAP)	0.90	1.13	1.71	3.61	4.65	5.38	5.40	5.39	5.38	5.36	5.34	5.34	(1.78)	7.35	20.82	21.42

Source: Company data, Morgan Stanley Research (E) estimates

Macronix: Valuation Methodology


We keep our PT unchanged at NT\$202: We continue to use a P/B multiple methodology to derive our price target, in line with our approach for Greater China memory IDM peers and in view of the industry's high volatility. Historically, forward P/B has had a similar trend vs. ROAE. We continue to expect the stock will trade up to 7.0x 2026e BVPS (same as prior P/B target) vs. its historical average of 1.5x since 2017. We continue to believe the higher than historical average P/B target is justifiable, as The MLC and legacy TLC NAND could be in greater shortage into 2H26, with under supply easily going up to 40%. The only supplier which could fill the gap remains Macronix, which we expect will enjoy significant pricing upside of over 200% from 1Q26 to 4-Q26, driving earnings upside. With very limited changes in BVPS for 2026e, our base case PT remains unchanged NT\$202.

Exhibit 18: Forward P/B vs. ROAE



Source: Factset, Morgan Stanley Research

Exhibit 19: Macronix: Earnings estimate revision breadth




Source: Company data, Morgan Stanley Research estimates

Risk Reward – Macronix International Co Ltd (2337.TW) Top Pick


Top Pick; OW on legacy Flash opportunities

PRICE TARGET **NT\$202.00**

Base case, P/B, in line with our Greater China memory coverage, due to the memory industry's cyclical nature. We apply a target multiple of 7.0x to our 2026 BVPS estimate, vs. its historical average of 1.5x since 2017. We continue to believe the P/B target is justifiable, as the MLC and legacy TLC NAND could be in greater shortage into 2H26, with under supply easily going up to 40%. The only supplier which could fill the gap remains Macronix.



RISK REWARD CHART




Key: — Historical Stock Performance ● Current Stock Price ◆ Price Target
Source: Refinitiv, Morgan Stanley Research

OVERWEIGHT THESIS

- The MLC and legacy TLC NAND could be in greater shortage into 2H26, with under supply easily going up to 40%. The only supplier which could fill the gap remains Macronix. The pricing for MLC and legacy TLC could rise over 200% from 1Q26 to 4Q26
- We expect low-single-digit NOR undersupply throughout 2026, driven by capacity cannibalization from other high-margin products.
- ROM may benefit from the Nintendo Switch 2, which started selling in June 2025.
- We view the current P/B valuation as attractive given the strong near-term outlook.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Pricing Power: *Positive*
Secular Growth: *Positive*

View descriptions of Risk Rewards Themes [here](#)

BULL CASE	NT\$326.00	BASE CASE	NT\$202.00	BEAR CASE	NT\$119.50
11.4x 2026e BVPS		7.0x 2026e BVPS		4.2x 2026e BVPS	
Higher than expected price hike for legacy NAND, and significant price hike for NOR throughout 2026: NAND revenue grows 1000%+, and NOR flash revenue grows 110%+ Y/Y in 2026.		Significant price hike for legacy NAND, and continued price hike for NOR throughout 2026: NAND revenue grows 641%, and NOR flash revenue grows 96% Y/Y in 2026.		Moderate price hike for legacy NAND, and flattish price for NOR throughout 2026: NAND revenue grows <150%, and NOR flash revenue grows <80% Y/Y in 2026.	

Risk Reward – Macronix International Co Ltd (2337.TW)


KEY EARNINGS INPUTS

Drivers	2025	2026e	2027e	2028e
NOR Flash pricing (NT\$)	1,728	2,783	3,256	3,256
ROM sales (NT\$, mn)	5,712	3,887	3,808	4,119
NAND sales (NT\$, mn)	3,705	27,459	92,068	97,771

INVESTMENT DRIVERS

- NOR pricing trend
- SLC NAND pricing
- Peers' production expansion

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

2/5
MOST

3 Month
Horizon

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Wider legacy NAND supply / demand gap
- NOR up-cycle, driven by limited supply expansion and/or stronger demand
- Faster growth for Switch hardware and core titles

RISKS TO DOWNSIDE

- Less severe legacy NAND supply / demand gap
- NOR down-cycle, driven by faster supply expansion and/or demand weakness
- Slower growth for Switch hardware and core titles





OWNERSHIP POSITIONING

Inst. Owners, % Active **48.4%**

Source: Refinitiv, Morgan Stanley Research

MS ESTIMATES VS. CONSENSUS

FY Dec 2026e



◆ Mean ◆ Morgan Stanley Estimates
Source: Refinitiv, Morgan Stanley Research


Macronix: Financial Summary

Exhibit 20: Financial Summary

Income Statement, 2025-2028e, Year End Dec				
(NT\$ mn)	2025	2026e	2027e	2028e
Turnover	28,880	66,682	126,013	127,564
YoY Growth	11.6%	130.9%	89.0%	1.2%
Less: COGS	(23,749)	(38,757)	(64,140)	(64,015)
Variable costs	(19,503)	(32,323)	(57,622)	(57,404)
Depreciation & amort	(4,246)	(6,434)	(6,517)	(6,611)
Gross profit	5,131	27,925	61,874	63,549
YoY Growth	-15.9%	444.2%	121.6%	2.7%
% margin	17.8%	41.9%	49.1%	49.8%
Operating Expenses:	(8,829)	(10,955)	(14,372)	(14,768)
R&D	(5,714)	(5,764)	(6,084)	(6,404)
Sales and Marketing	(1,520)	(3,180)	(6,176)	(6,252)
General and Admin	(1,594)	(2,011)	(2,112)	(2,112)
Operating Profit	(3,698)	16,970	48,496	49,869
YoY Growth	-5.8%	-558.9%	185.8%	2.8%
% margin	-12.8%	25.4%	38.5%	39.1%
Total Non-op	64	106	(75)	(56)
Pretax Profit	(3,633)	17,076	48,421	49,813
YoY Growth	2.5%	-570.0%	183.6%	2.9%
% margin	-12.6%	25.6%	38.4%	39.0%
Tax	328	(2,583)	(7,408)	(7,621)
Reported Net Income	(3,308)	14,478	40,998	42,178
Reported EPS (NT\$)	(1.78)	7.35	20.82	21.42
ModelWare EPS (NT\$)	(1.78)	7.35	20.82	21.42
Key Ratios	2025	2026e	2027e	2028e
Return (%)				
ROAA	(0.0)	0.1	0.2	0.2
ROAE	(0.1)	0.2	0.4	0.4
OP. ATO	46.7%	58.2%	100.9%	106.1%
Gearing (x)				
Net Debt/ Equity	0.1x	0.7x	(0.0x)	(0.3x)
Current Ratio	2.4x	3.2x	6.1x	8.7x
Quick Ratio	1.6x	1.1x	3.9x	6.6x
Operating Cycle				
AR/IR Turnover (days)	99	81	53	56
Inventory Turnover (days)	295	281	208	214
AP Turnover (days)	69	64	45	47
Cash Conversion (days)	325	299	216	223
Balance sheet	2025	2026e	2027e	2028e
(NT\$ mn)				
Assets				
Cash & Equivalents	14,913	2,946	48,648	95,687
Marketable Security	7	7	7	7
A/R & N/R	4,315	16,215	19,811	19,748
Inventories	9,813	35,102	38,194	38,084
Other Current Asset	190	190	190	190
Total current assets	29,425	54,647	107,035	153,903
LT Investment	6,618	6,616	6,613	6,612
Total Fixed Assets	38,549	53,012	48,299	43,587
Total Other Assets	3,909	3,909	3,909	3,909
Total Assets	78,500	118,183	165,857	208,011
Liabilities				
A/P & N/P	3,120	7,662	8,337	8,313
Accrued Expenses	0	0	0	0
Other Payable	1,877	1,877	1,877	1,877
Total Current Liab.	12,404	16,945	17,620	17,596
L-T Liabilities	17,386	41,386	47,386	47,386
Total Other L-T Liab	2,903	2,903	2,903	2,903
Total Liabilities	32,693	61,234	67,909	67,885
Equity				
Common Stock	18,573	18,573	18,573	18,573
Preferred Stock				
Capital Reserve	1,472	1,472	1,472	1,472
Retained earnings	25,916	37,058	78,056	120,234
Treasury Stock	(159)	(159)	(159)	(159)
Total Equity	45,808	56,949	97,948	140,125
Cash Flow Statement	2025	2026e	2027e	2028e
(NT\$ mn)				
Net Income	(3,308)	14,478	40,998	42,178
Depreciation	5,094	7,537	6,470	6,470
Net Investment Losses (Gains)	(2)	0	0	0
Others	3,051	(32,646)	(6,009)	150
Cash Flow-Operating	4,835	(10,630)	41,459	48,797
Investing				
(Purchase) of FA	(3,000)	(22,000)	(1,758)	(1,758)
Sale of Fix Asset	2	0	0	0
(Purchase)L-T Inv.	0	0	0	0
Sale of L-T Inv.	0	0	0	0
Sale(Pur.)S-T Inv.	144	0	0	0
Cash Flow-Investing	(2,884)	(22,000)	(1,758)	(1,758)
Financing				
Inc(Dec)-S-T Debt	(2,488)	0	0	0
Dividend Paid	(3,337)	(3,337)	(3,337)	(3,337)
Dir.&Emp Bonus	0	0	0	0
Proceed from New Issue	0	0	0	0
Dec/Inc-TreasureSt	0	0	0	0
Others	2,884	24,000	6,000	0
Cash Flow-Financing	(2,941)	20,663	2,663	(3,337)
Change in Cash	3,289	(11,967)	42,365	43,703
Net cash/(debt), b/f	11,623	14,913	2,946	45,311
Net cash/(debt), c/f	14,913	2,946	45,311	89,014

e = Morgan Stanley Research Estimates
Source: Company Data, Morgan Stanley Research

Source: Company data, Morgan Stanley Research (E) estimates



AP Memory: Estimate Revisions Summary

We raise our 2027/28 EPS estimates by 3%/16%: We factor in increased IPD revenue contribution due to a stronger outlook. We also estimate higher pricing for wafer-on-wafer memory. In comparison, FactSet consensus 2026/27/28 estimates are NT \$13.11/23.93/32.47. Our stronger EPS forecasts reflect our more constructive view on the IPD shipment outlook, we believe.

Exhibit 21: AP Memory – Estimate revisions

(NT\$ mn)	New '26e	Old '26e	Diff.	New '27e	Old '27e	Diff.	New '28e	Old '28e	Diff.
Net sales	9,333	9,333	0%	14,326	13,777	4%	22,173	18,865	18%
COGS	4,784	4,784		7,026	6,724		10,587	8,896	
Gross profit	4,550	4,550	0%	7,300	7,053	4%	11,585	9,969	16%
Operating expenses	1,709	1,709		2,286	2,211		3,322	2,913	
Operating profit	2,841	2,841	0%	5,014	4,842	4%	8,264	7,056	17%
Non-op. income (exp.)	343	343		343	343		343	343	
Pretax income	3,183	3,183	0%	5,357	5,185	3%	8,606	7,399	16%
Taxes	556	556		936	906		1,504	1,293	
Net income	2,627	2,627	0%	4,420	4,279	3%	7,102	6,106	16%
Reported EPS	16.16	16.16	0%	27.19	26.32	3%	43.68	37.56	16%
Margins									
Gross margin	48.7%	48.7%	0.0%	51.0%	51.2%	-0.2%	52.3%	52.8%	-0.6%
Operating margin	30.4%	30.4%	0.0%	35.0%	35.1%	-0.1%	37.3%	37.4%	-0.1%
Pretax margin	34.1%	34.1%	0.0%	37.4%	37.6%	-0.2%	38.8%	39.2%	-0.4%
Net margin	28.1%	28.1%	0.0%	30.9%	31.1%	-0.2%	32.0%	32.4%	-0.3%
Opex %	18.3%	18.3%	0.0%	16.0%	16.0%	-0.1%	15.0%	15.4%	-0.5%

Source: Company data, Morgan Stanley Research (e) estimates

Exhibit 22: AP Memory – Quarterly financial summary

(NT\$ mn)	1Q26e	2Q26e	3Q26e	4Q26e	1Q27e	2Q27e	3Q27e	4Q27e	1Q28e	2Q28e	3Q28e	4Q28e	2025	2026e	2027e	2028e
Total Revenues	2,101	2,222	2,451	2,558	3,055	3,296	3,791	4,184	4,687	5,297	5,802	6,387	5,658	9,333	14,326	22,173
Sequential Change	12.5%	5.8%	10.3%	4.4%	19.4%	7.9%	15.0%	10.4%	12.0%	13.0%	9.5%	10.1%				
Change vs Year Ago	115.5%	67.3%	64.0%	37.0%	45.4%	48.3%	54.6%	63.5%	53.4%	60.7%	53.0%	52.7%	35.0%	65.0%	53.5%	54.8%
Cost of Sales	1,098	1,145	1,248	1,293	1,521	1,632	1,843	2,030	2,236	2,526	2,766	3,059	3,024	4,784	7,026	10,587
Percent of Revenues	52%	52%	51%	51%	50%	50%	49%	49%	48%	48%	48%	48%	53%	51%	49%	48%
Gross Profit	1,003	1,078	1,204	1,265	1,534	1,664	1,948	2,154	2,451	2,771	3,036	3,328	2,634	4,550	7,300	11,585
Percent of Revenues	47.7%	48.5%	49.1%	49.5%	50.2%	50.5%	51.4%	51.5%	52.3%	52.3%	52.3%	52.1%	46.5%	48.7%	51.0%	52.3%
Incremental Margin	31%	61%	55%	57%	54%	54%	57%	52%	59%	52%	52%	50%	33%	52%	55%	55%
Total Opex	401	411	439	458	519	524	595	648	716	799	853	944	1,234	1,709	2,286	3,322
Percent of Revenues	19.1%	18.5%	17.9%	17.9%	17.0%	15.9%	15.7%	15.5%	15.3%	15.1%	14.9%	14.8%	21.8%	18.3%	16.0%	15.0%
Operating Income	602	667	765	807	1,015	1,140	1,353	1,506	1,735	1,972	2,172	2,384	1,399	2,841	5,014	8,264
Percent of Revenues	28.6%	30.0%	31.2%	31.6%	33.2%	34.6%	35.7%	36.0%	37.0%	37.2%	37.4%	37.3%	24.7%	30.4%	35.0%	37.3%
Total Non-operating Income (Loss)	86	86	86	86	86	86	86	86	86	86	86	86	119	343	343	343
Profit Before Taxes	687	752	851	893	1,101	1,226	1,439	1,591	1,820	2,058	2,258	2,470	1,518	3,183	5,357	8,606
Percent of Revenues	33%	34%	35%	35%	36%	37%	38%	38%	39%	39%	39%	39%	27%	34%	37%	39%
Taxes	120	131	149	156	192	214	251	278	318	360	395	432	279	556	936	1,504
Tax Rate	17.5%	17.5%	17.5%	17.5%	17.5%	17.5%	17.5%	17.5%	17.5%	17.5%	17.5%	17.5%	18.3%	17.5%	17.5%	17.5%
Reported Income (TW GAAP)	567	621	702	737	908	1,012	1,187	1,313	1,502	1,698	1,853	2,038	1,240	2,627	4,420	7,102
Percent of Revenues	27.0%	27.9%	28.6%	28.8%	29.7%	30.7%	31.3%	31.4%	32.1%	32.1%	32.1%	31.9%	21.9%	28.1%	30.9%	32.0%
Change vs Year Ago	71%	-214%	-1%	-4%	60%	63%	69%	78%	65%	68%	57%	55%	-21%	112%	68%	61%
Reported EPS (NT\$, TW GAAP)	3.49	3.82	4.32	4.53	5.59	6.22	7.30	8.08	9.24	10.45	11.46	12.54	7.63	16.16	27.19	43.68
Change vs Year Ago	71%	-214%	-1%	-4%	60%	63%	69%	78%	65%	68%	57%	55%	-22%	112%	68%	61%

Source: Company data, Morgan Stanley Research (e) estimates

AP Memory: Valuation Methodology

We raise our price target to NT\$1,000 from NT\$777 to factor in our earnings estimate changes. We also lift our intermediate growth rate from 12.8% to 14.3% as we factor in the Intel EMIB opportunity for AI in the long run.

Aside from intermediate growth, our other residual income model assumptions are unchanged, including: 1) cost of equity unchanged at 9.2% (2.0% risk-free rate, 6% risk premium, 1.2 beta); 2) payout ratio of 67%; and 3) terminal growth rate of 3% to be more in line with the long-term macro growth rate. Our new PT implies 2026e P/E of 62x and 2027e P/E of 37x – more than 1 s.d. above the historical average since 2020. Our bull and bear case values rise to NT\$1,175 (from NT\$1,145) and NT\$400 (from NT\$376), respectively.

Exhibit 23: AP Memory: Residual Income model

(NT\$ mn)	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e
Total Equity	14,156	16,807	20,933	24,155	27,837	32,045	36,854	42,350	48,631	55,808	64,011	73,385
Net Profit	2,627	4,420	7,102	8,116	9,275	10,600	12,114	13,843	15,820	18,079	20,661	23,611
ROAE	19.8%	28.6%	37.6%	36.0%	35.7%	35.4%	35.2%	35.0%	34.8%	34.6%	34.5%	34.4%
Residual Income	1,311	2,739	4,779	5,610	6,395	7,293	8,319	9,491	10,830	12,361	14,110	16,109
Spread	10.6%	19.3%	28.4%	26.8%	26.5%	26.2%	26.0%	25.8%	25.6%	25.4%	25.3%	25.2%
Ending Equity Capital	14,156											
PV of Forecast Period	46,845											
PV of Continuing Value	101,532											
Equity Value	162,533											
No. of Shares	163											
Projected Price (NT\$)	1,000											


Source: Company data, Morgan Stanley Research (e) estimates

Exhibit 24: AP Memory: Historical forward P/E



Source: Company data, Morgan Stanley Research

Exhibit 25: AP Memory: Earnings estimate revision breadth



Source: Company data, Morgan Stanley Research estimates


Risk Reward – AP Memory Technology Corp (6531.TW)

OW on IPD and WoW opportunities

PRICE TARGET NT\$1,000.00

Base case, derived from a residual income model. Key RI model assumptions include 1) cost of equity constant at 9.2% (2.0% risk-free rate, 6% risk premium, 1.2 beta); 2) payout ratio of 67%; 3) terminal growth rate of 3.0%; and 4) medium-term growth rate of 14.3%.

RISK REWARD CHART




Key: — Historical Stock Performance ● Current Stock Price ◆ Price Target

Source: Refinitiv, Morgan Stanley Research

OVERWEIGHT THESIS

- IPD (interposers and discretives) revenue is likely to ramp in 2026-27, and be further driven by new IPD interposer opportunities into 2028.
- Memory bandwidth and power consumption are the next issues to be resolved in AI computing, and we believe AP Memory's wafer-on wafer (WoW) packaging technology could be an effective solution.
- The company expects memory business to be stable in the near term.
- Overall AI business should continue to rise in the mix – a positive read for the margin profile.
- Our PT implies 62x 2026e P/E and 37x 2027e P/E - more than 1 s.d. above the average level since 2020.

Consensus Rating Distribution



MS Rating

Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Secular Growth: *Positive*
Technology Diffusion: *Positive*

View descriptions of Risk Rewards Themes [here](#)

BULL CASE

NT\$1,175.00

73x 2026e EPS

Faster-than-expected AI and IPD business progress with PSRAM generating more cash flow: We assume: 1) WoW packaging revenue to reach >NT\$10bn, and IPD revenue to reach <NT\$8bn by 2028; 2) total revenue to rise at a 55%+ CAGR, 2025-28; and 3) gross margin to increase from 46.5% in 2025 to 60%+ by 2028.

BASE CASE

NT\$1,000.00

62x 2026e EPS

Fast-growing AI and IPD business, with PSRAM generating stable cash flows: We expect: 1) WoW revenue to reach NT\$6.3bn, and IPD revenue to reach NT\$10bn+ by 2028; 2) total revenue to rise at a 58% CAGR, 2025-28; and 3) gross margin to increase from 46.5% in 2025 to over 52% in 2028.

BEAR CASE

NT\$400.00

25x 2026e EPS

Slower-than-expected AI and IPD business progress, with PSRAM facing intensifying competition: We assume: 1) WoW packaging revenue of ~NT\$1.5bn, and IPD revenue of ~NT\$2bn by 2028; 2) total revenue to rise at a 10-15% CAGR, 2025-28; and 3) gross margin to remain at ~51% by 2028.

Risk Reward – AP Memory Technology Corp (6531.TW)


KEY EARNINGS INPUTS

Drivers	2025	2026e	2027e	2028e
1. Wifi Sales (%) (%)	73.7	55.7	39.2	26.1
2. Ethernet Sales (%) (%)	7.1	8.7	20.5	28.5

INVESTMENT DRIVERS

- Demand for AI applications
- Consumer tech demand, especially from the IoT market

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

RISKS TO PT/RATING

RISKS TO UPSIDE

- Stronger-than-expected consumer demand
- Faster-than-expected IPD ramp and WoW packaging development
- Milder competition from partners (foundry, memory house, GPU vendor) or other design houses

RISKS TO DOWNSIDE

- Weaker-than-expected consumer demand
- Slower-than-expected IPD ramp and WoW packaging development
- Intensifying competition from partners (foundry, memory house, GPU vendor) or other design houses



OWNERSHIP POSITIONING



Source: Refinitiv, Morgan Stanley Research

MS ESTIMATES VS. CONSENSUS

FY Dec 2026e



◆ Mean ◆ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Valuation Methodology and Risks

Micron Technology Inc. (MU.O)

~25x through-cycle earnings of US \$21.00, a premium to history reflecting new opportunities in AI, At the high end of broader semis.

Risks to Upside

- Customers continue to demonstrate an appetite to take on inventory around macroeconomic uncertainty
- Additional wafer intensity of HBM further improves overall supply and demand
- Micron's HBM share surpasses expectations

Risks to Downside

- Pricing can turn quickly; a falter in end demand with inventories elevated could lead to a swift price reduction
- HBM demand falters and competition intensifies, pressuring pricing

Risk Reward Reference links

1. View explanation of Options Probabilities methodology - [Options_Probabilities_Exhibit_Link.pdf](#)
2. View descriptions of Risk Rewards Themes - [RR_Themes_Exhibit_Link.pdf](#)
3. View explanation of regional hierarchies - [GEG_Exhibit_Link.pdf](#)
4. View explanation of Theme/Exposure methodology - [ESG_Sustainable_Solutions_External_Link.pdf](#)
5. View explanation of HERS methodology - [ESG_HERS_External_Link.pdf](#)

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com which accepts the responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research, and their affiliates (collectively, "Morgan Stanley"). Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/eqr/disclosures/webapp/generalresearch, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Charlie Chan, Daisy Dai, CFA; Tiffany Yeh; Daniel Yen, CFA.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

As of March 31, 2026, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: ACM Research Inc, Advanced Micro-Fabrication Equipment Inc, Advanced Wireless Semiconductor Co, Alchip Technologies Ltd, AllRing Tech Co., AP Memory Technology Corp, ASE Technology Holding Co. Ltd., ASMP Ltd, Global Unichip Corp, Hon Precision, J CET Group Co Ltd, King Yuan Electronics Co Ltd, Macronix International Co Ltd, **Micron Technology Inc.**, Montage Technology Co Ltd, MPI Corporation, Nanya Technology Corp., NAURA Technology Group Co Ltd, Novatek, Phison Electronics Corp, Powerchip Semiconductor Manufacturing Co, Realtek Semiconductor, Shanghai Fudan Microelectronics, Silergy Corp., TSMC, UMC, Vanguard International Semiconductor, WIN Semiconductors Corp, Winbond Electronics Corp, WPG Holdings, WT Microelectronics Co. Ltd.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of **Micron Technology Inc.**, Montage Technology Co Ltd.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from ASMP Ltd, **Micron Technology Inc.**, Montage Technology Co Ltd.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Alchip Technologies Ltd, AP Memory Technology Corp, ASE Technology Holding Co. Ltd., ASMedia Technology Inc, ASMP Ltd, Espressif Systems, GigaDevice Semiconductor Beijing Inc, GlobalWafers Co Ltd, Gudeng Precision, Himax Technologies Inc, Iluvatar CoreX Semiconductor Co., Ltd., Innoscience, King Yuan Electronics Co Ltd, Macronix International Co Ltd, MediaTek, **Micron Technology Inc.**, Montage Technology Co Ltd, Novatek, Phison Electronics Corp, Powerchip Semiconductor Manufacturing Co, Realtek Semiconductor, Silergy Corp., Silicon Motion, TSMC, UMC, Universal Scientific Ind. (Shanghai), Vanguard International Semiconductor, Winbond Electronics Corp, WPG Holdings, WT Microelectronics Co. Ltd.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from ASE Technology Holding Co. Ltd., King Yuan Electronics Co Ltd, MediaTek, **Micron Technology Inc.**, Nanya Technology Corp., Novatek, Nuvoton Technology Corporation, Realtek Semiconductor, Silicon Motion, SMIC, TSMC, UMC, Universal Scientific Ind. (Shanghai), Winbond Electronics Corp, WT Microelectronics Co. Ltd.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Alchip Technologies Ltd, AP Memory Technology Corp, ASE Technology Holding Co. Ltd., ASMedia Technology Inc, ASMP Ltd, Espressif Systems, GigaDevice Semiconductor Beijing Inc, GlobalWafers Co Ltd, Gudeng Precision, Himax Technologies Inc, Iluvatar CoreX Semiconductor Co., Ltd., Innoscience, King Yuan Electronics Co Ltd, Macronix International Co Ltd, MediaTek, **Micron Technology Inc.**, Montage Technology Co Ltd, Novatek, Phison Electronics Corp, Powerchip Semiconductor Manufacturing Co, Realtek Semiconductor, Silergy Corp., Silicon Motion, TSMC, UMC, Universal Scientific Ind. (Shanghai), Vanguard International Semiconductor, Winbond Electronics Corp, WPG Holdings, WT Microelectronics Co. Ltd.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: ASE Technology Holding Co. Ltd., King Yuan Electronics Co Ltd, MediaTek, **Micron Technology Inc.**, Montage Technology Co Ltd, Nanya Technology Corp., Novatek, Nuvoton Technology Corporation, Realtek Semiconductor, Silicon Motion, SMIC, TSMC, UMC, Universal Scientific Ind. (Shanghai), Winbond Electronics Corp, WT Microelectronics Co. Ltd.

Morgan Stanley & Co. LLC makes a market in the securities of ACM Research Inc, Himax Technologies Inc, Silicon Motion.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in

Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report. Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of March 31, 2026)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.

For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)			Other Material Investment Services Clients (MISC)	
	Count	% of Total	Count	% of Total IBC	% of Rating Category	Count	% of Total Other MISC
Overweight/Buy	1534	42%	461	50%	30%	698	43%
Equal-weight/Hold	1573	43%	372	40%	24%	716	44%
Not-Rated/Hold	4	0%	1	0%	25%	1	0%
Underweight/Sell	568	15%	89	10%	16%	209	13%
Total	3,679		923			1624	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding any material conflict of interest that can reasonably be expected to have influenced Morgan Stanley Smith Barney LLC's choice of a third-party research provider or the subject company of a third-party research report, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to <https://www.morganstanley.com/eqr/disclosures/webapp/generalresearch>.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

A member of Research who had or could have had access to the research prior to completion owns securities (or related derivatives) in the Micron Technology Inc.. This person is not a research analyst or a member of research analyst's household.

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the

sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). Please use the provided link to review the Terms and Conditions and Most Important Terms and Conditions for Morgan Stanley India Company Private Limited (https://www.morganstanley.com/assets/pdfs/about-us-global-offices/india/Terms_and_conditions.pdf) and the following link to review the audit report (https://ny.matrix.ms.com/eqr/research/webapp/researchdocs/MSICPL_Morgan_Stanley_Research_Audit_Report.pdf).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited. Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V. which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia

(Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com. Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

Morgan Stanley Hong Kong Securities Limited is the liquidity provider/market maker for securities of ASMPT Ltd, Hua Hong Semiconductor Ltd listed on the Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: <http://www.hkex.com.hk>.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products. Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

INDUSTRY COVERAGE: Greater China Technology Semiconductors

COMPANY (TICKER)	RATING (AS OF)	PRICE* (04/27/2026)
Charlie Chan		
ACM Research Inc (ACMR.O)	O (03/07/2023)	US\$53.23
Advanced Micro-Fabrication Equipment Inc (688012.SS)	O (11/06/2023)	Rmb352.01
Advanced Wireless Semiconductor Co (8086.TWO)	U (07/14/2025)	NT\$134.00
Alchip Technologies Ltd (3661.TW)	O (05/14/2021)	NT\$4,160.00
ASE Technology Holding Co. Ltd. (3711.TW)	O (09/15/2024)	NT\$495.50
Cambricon Technology Corporation (688256.SS)	O (04/27/2026)	Rmb1,356.72
Global Unichip Corp (3443.TW)	O (07/27/2024)	NT\$3,955.00
GlobalWafers Co Ltd (6488.TWO)	O (09/19/2025)	NT\$620.00

Gudeng Precision (3680.TWO)	O (11/25/2025)	NT\$449.00
Hua Hong Semiconductor Ltd (1347.HK)	E (03/12/2026)	HK\$114.60
Iluvatar CoreX Semiconductor Co., Ltd. (9903.HK)	O (04/27/2026)	HK\$414.20
King Yuan Electronics Co Ltd (2449.TW)	O (03/03/2023)	NT\$283.50
Maxscend Microelectronics Co Ltd (300782.SZ)	U (01/11/2021)	Rmb106.58
MediaTek (2454.TW)	O (11/28/2025)	NT\$2,435.00
MetaX Integrated Circuits (688802.SS)	E (04/27/2026)	Rmb724.12
Nanya Technology Corp. (2408.TW)	E (03/20/2026)	NT\$226.50
NAURA Technology Group Co Ltd (002371.SZ)	O (11/06/2023)	Rmb516.25
OmniVision Integrated Circuits Group Inc (603501.SS)	E (11/17/2025)	Rmb104.63
Phison Electronics Corp (8299.TWO)	E (02/25/2026)	NT\$1,835.00
SG Micro Corp. (300661.SZ)	E (11/03/2025)	Rmb90.12
Silergy Corp. (6415.TW)	E (04/21/2026)	NT\$420.00
SMIC (0981.HK)	O (10/21/2025)	HK\$68.25
TSMC (2330.TW)	O (02/07/2022)	NT\$2,265.00
UMC (2303.TW)	E (04/20/2026)	NT\$72.70
Vanguard International Semiconductor (5347.TWO)	E (01/14/2026)	NT\$138.50
WIN Semiconductors Corp (3105.TWO)	U (07/14/2025)	NT\$492.50
Daisy Dai, CFA		
ASMP Ltd (0522.HK)	O (07/24/2025)	HK\$165.80
China Resources Microelectronics Limited (688396.SS)	U (03/02/2026)	Rmb55.16
Elan Microelectronics Corp (2458.TW)	O (10/03/2025)	NT\$136.00
Empyrean Technology Co Ltd (301269.SZ)	E (01/17/2025)	Rmb92.77
Hangzhou Silan Microelectronics Co. Ltd. (600460.SS)	U (08/25/2025)	Rmb28.93
Innoscence (2577.HK)	E (10/13/2025)	HK\$67.45
JCET Group Co Ltd (600584.SS)	E (01/16/2026)	Rmb46.32
Shanghai Fudan Microelectronics (1385.HK)	O (03/07/2025)	HK\$44.76
SICC Co Ltd (688234.SS)	O (03/20/2026)	Rmb107.70
StarPower Semiconductor Ltd (603290.SS)	O (03/01/2022)	Rmb110.70
Unigroup Guoxin Microelectronics Co Ltd (002049.SZ)	U (01/10/2023)	Rmb73.36
Universal Scientific Ind. (Shanghai) (601231.SS)	O (11/05/2025)	Rmb39.65
Yangjie Technology (300373.SZ)	O (06/10/2022)	Rmb79.13
Daniel Yen, CFA		
AP Memory Technology Corp (6531.TW)	O (07/11/2025)	NT\$753.00
ASMedia Technology Inc (5269.TW)	U (10/03/2025)	NT\$1,290.00
Aspeed Technology (5274.TWO)	O (06/09/2025)	NT\$16,000.00
Egis Technology Inc (6462.TWO)	E (01/28/2026)	NT\$120.00
Espressif Systems (688018.SS)	O (05/15/2023)	Rmb176.25
GigaDevice Semiconductor Beijing Inc (603986.SS)	O (05/15/2025)	Rmb303.42
Macronix International Co Ltd (2337.TW)	O (09/18/2025)	NT\$145.00
Montage Technology Co Ltd (6809.HK)	O (03/18/2026)	HK\$259.20
Montage Technology Co Ltd (688008.SS)	O (03/18/2026)	Rmb178.09
Novatek (3034.TW)	U (02/04/2026)	NT\$416.50
Nuvoton Technology Corporation (4919.TW)	U (11/10/2025)	NT\$136.00
Parade Technologies Ltd (4966.TWO)	E (01/30/2026)	NT\$615.00
Powerchip Semiconductor Manufacturing Co (6770.TW)	O (10/27/2025)	NT\$54.50
Realtek Semiconductor (2379.TW)	E (01/30/2026)	NT\$555.00
Shenzhen Goodix Technology Co Ltd (603160.SS)	U (07/14/2025)	Rmb66.41
Winbond Electronics Corp (2344.TW)	E (03/20/2026)	NT\$93.90
WPG Holdings (3702.TW)	O (03/16/2026)	NT\$95.50
WT Microelectronics Co. Ltd. (3036.TW)	O (01/27/2026)	NT\$201.00
Duan Liu		
Dosilicon Co Ltd (688110.SS)	U (09/06/2024)	Rmb132.94
Shenzhen Longsys Electronics Co Ltd (301308.SZ)	E (02/25/2026)	Rmb393.46
Tiffany Yeh		

AllRing Tech Co. (6187.TWO)	O (09/23/2025)	NT\$1,080.00
FOCI Fiber Optic Communications Inc (3363.TWO)	O (01/15/2025)	NT\$739.00
Himax Technologies Inc (HIMX.O)	E (02/04/2026)	US\$11.50
Hon Precision (7769.TW)	O (04/17/2026)	NT\$4,970.00
MPI Corporation (6223.TWO)	O (04/17/2026)	NT\$4,880.00
Silicon Motion (SIMO.O)	O (05/06/2024)	US\$147.54
Winway Technology Co Ltd (6515.TW)	O (04/17/2026)	NT\$9,580.00

Stock Ratings are subject to change. Please see latest research for each company.

* Historical prices are not split adjusted.

© 2026 Morgan Stanley